Ma Songjiang's Form 4/A amendment
AmendedGyre Therapeutics, Inc. (GYRE) · filed Jan 10, 2025
- Accession no.
- 0001140361-25-000827
- Filed
- Jan 10, 2025
- Trade date
- Jan 3, 2025
- Filing delay
- 7 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Jan 6, 2025
This filing lists 1 non-derivative transaction. It carries over 2 transactions from the original filing that it did not restate. Open-market sales total $44.5K. It was filed 7 days after the trade.
This amendment restates part of 0001140361-25-000339 (filed Jan 6, 2025). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ma SongjiangCIK 0001985547 | Director, Officer (President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2025 | Common Stock | SSaleDisposed | −833 | $11.85 | −$9,871.05 | 2,918,467 | Indirect |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001140361-25-000339 (filed Jan 6, 2025).
Non-derivative securities (Table I)
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.99 to $12.80. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.73 to $12.27. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This Form 4 amends the Form 4 filed on January 6, 2025 to reflect the correct transaction date as of January 3, 2025. The original filing incorrectly reported the transaction date as of January 3, 2024.